Anzeige
Mehr »
Login
Donnerstag, 23.03.2023 Börsentäglich über 12.000 News von 687 internationalen Medien
Cybeats Technologies: Ritterschlag durch die Linux-Foundation!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JJ99 ISIN: US04962H5063 Ticker-Symbol: YAG2 
Tradegate
21.03.23
16:13 Uhr
0,634 Euro
+0,003
+0,40 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6250,65008:30
0,6170,64408:27

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAtossa Therapeutics GAAP EPS of -$0.21 beats by $0.012
MiATOSSA THERAPEUTICS, INC. - 10-K, Annual Report2
MiAtossa Therapeutics, Inc.: Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update3
MiATOSSA THERAPEUTICS, INC. - 8-K, Current Report2
DiAtossa Therapeutics, Inc.: Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial5
15.03.Atossa Therapeutics, Inc.: Atossa to Present at the Sidoti Small-Cap Virtual Conference7
13.03.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report6
28.02.Atossa Therapeutics FY 2022 Earnings Preview12
ATOSSA THERAPEUTICS Aktie jetzt für 0€ handeln
23.02.Atossa Therapeutics, Inc.: Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer12
13.02.Atossa announces new U.S. patent covering lead asset9
13.02.Atossa Therapeutics, Inc.: Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen338SEATTLE, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...
► Artikel lesen
25.01.Atossa Therapeutics, Inc.: Atossa Therapeutics Issues Letter to Shareholders620SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...
► Artikel lesen
07.12.22Atossa Therapeutics, Inc.: Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations29
07.11.22Atossa Therapeutics GAAP EPS of -$0.06 in-line14
07.11.22Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update325SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on...
► Artikel lesen
01.11.22Atossa acquiring ~20% stake in Dynamic Cell Therapies to boost CAR-T development12
01.11.22Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy8
25.10.22Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.7
24.10.22Atossa receives FDA OK to begin phase 2 trial of (Z)-endoxifen for breast cancer8
24.10.22Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- ...4
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5